High throughput screening News and Research

RSS

High-throughput screening (HTS) allows scientists to test thousands of samples at once. These samples can be of a wide variety, and include, but are not limited to, amino acids, chemical compounds or cells.

Scientists identify a new way to develop potential drugs for TB

Scientists have developed a way to pinpoint promising drugs to fight tuberculosis (TB) and other diseases without setting foot in the laboratory.

24 Mar 2013

UNM scientists identify chemical compound that appears to control cell metastases

It's the spread of the original cancer tumor that kills most people. That's why cancer researchers vigorously search for drugs that can prevent metastases, the spread of cancer. The research team co-led by Angela Wandinger-Ness, PhD, and Larry Sklar, PhD, at the University of New Mexico Cancer Center has found a chemical compound that appears to control cell migration and adhesion, two important characteristics of metastatic cancer cells.

14 Mar 2013

Scripps Research, Takeda Pharmaceutical to search for new drug targets for different diseases

The Scripps Research Institute and the Takeda Pharmaceutical Company have announced plans to expand their recent research collaboration to search for new drug targets for a variety of diseases.

14 Mar 2013

Sanford-Burnham, Mayo Clinic partner to expand and speed development of new drugs

To expand and speed the development of new drugs for its patients, Mayo Clinic has entered a formal collaboration with Sanford-Burnham Medical Research Institute. Under the agreement, Mayo's discoveries of potential drug targets will be the basis for the development of new drug screening platforms. This will allow future work that focuses on high-throughput screening and medicinal chemistry at Sanford-Burnham facilities.

12 Mar 2013

Two renowned SCCP scientists earn national recognition from Society of Toxicology

Two renowned scientists at the South Carolina College of Pharmacy (SCCP) have garnered national recognition from the Society of Toxicology (SoT), which named them recipients of two of its individual annual awards. It is the first time these awards have gone to individuals from the same College.

27 Feb 2013

GSK, Vanderbilt partner to develop and commercialize new therapies for severe obesity

Vanderbilt University announced today that it has signed a collaboration agreement with GlaxoSmithKline (GSK) for the discovery, development and commercialization of novel therapies for severe obesity.

13 Feb 2013

Combined genomic and proteomic plasma analysis can identify molecular disease mechanisms

For the first time, scientists have combined genomic and proteomic analysis of blood plasma to enhance identification of genetically regulated protein traits. This could be applied to any large association study of civilization diseases where blood plasma has been collected, vastly improving a clinician's ability to identify disease susceptibility in individuals and populations.

11 Feb 2013

Innovative drug discovery in Europe supported by Bayer

Bayer HealthCare initiated and will coordinate a newly founded pan-European consortium, named European Lead Factory, which has been launched to enhance early drug discovery addressing the need for innovative drugs. The new five-year project will create an exceptional small molecule library collection allowing drug discovery on innovative and promising targets from pharma companies and academia.

7 Feb 2013

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Marblar is gamifying the process of technology transfer. We post technology on our platform in the form of a challenge, and the Marblar community then competes to uncover new problems these technologies could solve – thereby discovering new market applications for these technologies.

31 Jan 2013

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded approximately $1.2 million from the U.S. National Institute of General Medical Sciences of the National Institutes of Health to identify, test and develop a series of drug candidates for a number of diseases, including rheumatoid arthritis, heart disease and several neurodegenerative disorders.

28 Jan 2013

Pairing statins with cyclin-dependent kinase inhibitors might effectively treat melanomas

A novel approach to identifying potential anticancer drug combinations revealed that pairing cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven by mutations in the NRAS and KRAS gene.

14 Dec 2012

Bicycle Therapeutics secures £3.75 million equity financing for drug discovery

Bicycle Therapeutics, a next generation biotherapeutics company co-founded by Sir Gregory Winter and Professor Christian Heinis, today announced that it had secured a tranched equity financing of £3.75 million to invest in selection of drug candidates using its bicyclic peptide technology platform.

10 Dec 2012

Scientists hope to unravel mystery of how Borrelia burgdorferi causes Lyme disease

Investigators at The University of Texas Health Science Center at Houston (UTHealth) have accelerated the search for the bacterial genes that make the Lyme disease bacterium so invasive and persistent. The discovery could advance the diagnosis and treatment of this disease, which affects an estimated 30,000 Americans each year.

29 Oct 2012

Scientists create new compounds that could slow progression of Parkinson's

In an early-stage breakthrough, a team of Northwestern University scientists has developed a new family of compounds that could slow the progression of Parkinson's disease.

25 Oct 2012

TSRI scientists to study structural rules that govern nuclear receptors

A consortium of scientists from both campuses of The Scripps Research Institute (TSRI) has been awarded $2.7 million from the National Institute of General Medical Sciences of the National Institutes of Health to study the structural rules that govern a large superfamily of proteins that help regulate critical functions such as reproduction, development and metabolism.

24 Oct 2012

Inhibiting TRPV4 protects against diet-induced obesity, inflammation and insulin resistance

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.

28 Sep 2012

TB Alliance, Sanofi partner to discover and develop novel compounds against tuberculosis

Sanofi and the Global Alliance for TB Drug Development announced today a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis (TB), a deadly infectious disease that resulted in almost 1.5 million deaths worldwide in 2010.

21 Sep 2012

AyoxxA Biosystems closes 2.6M Euro Series A financing round

AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.

20 Sep 2012

NIH awards Immunetics $3.7M SBIR contract for Babesia infection blood screening test

Immunetics, Inc., has received a $3.7 million, two year SBIR contract from the National Heart, Lung and Blood Institute, an agency of the National Institutes of Health (NIH), to support clinical trials of a new blood screening test for Babesia infection.

10 Sep 2012

Drug discovery solutions from SPT Labtech to be demonstrated at MipTech

SPT Labtech will be offering delegates at MipTec 2012 (24th-27th September, Basel, Switzerland) the opportunity to experience their innovative automated solutions for effortless drug discovery first-hand.

From SPT Labtech 7 Sep 2012

High throughput screening News and Research

Further Reading

Scientists identify a new way to develop potential drugs for TB

UNM scientists identify chemical compound that appears to control cell metastases

Scripps Research, Takeda Pharmaceutical to search for new drug targets for different diseases

Sanford-Burnham, Mayo Clinic partner to expand and speed development of new drugs

Two renowned SCCP scientists earn national recognition from Society of Toxicology

GSK, Vanderbilt partner to develop and commercialize new therapies for severe obesity

Combined genomic and proteomic plasma analysis can identify molecular disease mechanisms

Innovative drug discovery in Europe supported by Bayer

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

Pairing statins with cyclin-dependent kinase inhibitors might effectively treat melanomas

Bicycle Therapeutics secures £3.75 million equity financing for drug discovery

Scientists hope to unravel mystery of how Borrelia burgdorferi causes Lyme disease

Scientists create new compounds that could slow progression of Parkinson's

TSRI scientists to study structural rules that govern nuclear receptors

Inhibiting TRPV4 protects against diet-induced obesity, inflammation and insulin resistance

TB Alliance, Sanofi partner to discover and develop novel compounds against tuberculosis

AyoxxA Biosystems closes 2.6M Euro Series A financing round

NIH awards Immunetics $3.7M SBIR contract for Babesia infection blood screening test

Drug discovery solutions from SPT Labtech to be demonstrated at MipTech

Lab Diagnostics and Automation - Third Edition eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics